Pharmaceutical R+D

A solid R&D platform is the foundation of a successful pharmaceutical program. Government and industry clients at all stages of the drug discovery cycle turn to SRI Biosciences to rapidly identify and optimize new drug leads and move them toward preclinical development.

SRI Biosciences applies its more than 40 years of experience to solve challenges in formulation, drug delivery development, and the characterization of small molecule drugs and biologics.

SRI's approach to drug formulation is customized to the needs of clients and partners. Services range from the preparation of dose formulations for preclinical in vitro and in vivo safety studies, to the design of finished product dosage forms for clinical trials.

SRI also provides pharmaceutical R&D support and services in these areas:

Our pharmaceutical R&D services meet worldwide stringent regulatory requirements. SRI studies are conducted under current Good Laboratory Practice (GLP) and Good Manufacturing Practice (cGMP) regulations.

Projects

bioscience workers in a lab
Anti-Infectives Development for National Institutes of Health

SRI is conducting preclinical development of treatments for diseases such as tuberculosis, West Nile virus, hepatitis, and biodefense pathogens and toxins.

Topics: Chemistry, Manufacturing + Controls (CMC) Discovery ADMET and In Vitro Metabolism Disease Focus Areas Drug Discovery Drug Formulation Development Infectious Diseases Pharmaceutical R+D
scientist with a computer model of a molecular structure
Bis-Indole Drug Discovery in Multiple Therapeutic Areas

SRI is identifying candidates for advanced therapies in multiple disease areas by developing compounds from synthetically optimized, natural dietary products.

Topics: Cancer Drug Discovery Infectious Diseases Medicinal Chemistry Pharmaceutical R+D
scientist checking a batch of vaccines
Needle-Free Transmucosal Drug Delivery System

SRI has patented a novel approach to vaccine delivery that is safe for pediatric use, eliminating the need for painful injections.

Topics: Alternative Drug Delivery Systems Drug Formulation Development Medicinal Chemistry Pharmaceutical R+D
scientist working with a chelating agent
Oral Formulation of DTPA to Counter Radiation Exposure

A new oral version of a known chelating agent can defend against mass radiation exposure in a terrorist attack.

Topics: Chemical, Biological, Radiological, Nuclear + Explosives Defense Drug Formulation Development Pharmaceutical R+D
scientist looking through a microscope
Toxicological Evaluation of Novel Ligands Program

For the National Institute of Mental Health (NIMH), SRI performs preclinical safety and pharmacokinetics studies for brain imaging agents and drugs to treat mental illnesses.

Topics: Developmental + Reproductive Toxicology Discovery ADMET and In Vitro Metabolism Drug Metabolism and Pharmacokinetics Genetic Toxicology Pharmaceutical R+D Safety Pharmacology Toxicology and Safety
hand holding a petri dish of bacterial culture up to the light
Vitamin A Biosynthesis in Probiotic Bacteria

Vitamin A deficiency causes susceptibility — especially in children — to diarrhea-causing infections, which lead to millions of deaths each year. SRI is developing a probiotic that produces the vitamin.

Topics: Disease Focus Areas Drug Discovery Drug Formulation Development Pharmaceutical R+D

Products + Solutions

researchers in lab coats working at a lab table
SR16388: A Novel Drug That Inhibits Tumor Growth by Targeting ERRalpha

SRI researchers have developed a novel steroidal compound, SR16388, which very selectively binds to and inhibits ERRalpha. This drug also regulates tumor energy metabolism by strongly inhibiting the protein HIF-1alpha, which promotes tumor cell survival in low-oxygen conditions.

Topics: Basic Cancer Research Cancer Drug Discovery Drug Discovery Drug Lead Identification + Optimization Pharmaceutical R+D

Press Releases

Governor Kaine Announces Major Research Institute for Virginia

SRI International will transform state's research and development efforts

Topics: 21st Century Skills Disease Focus Areas Pharmaceutical R+D
Jia-Hwa Fang
Jia-Hwa Fang Joins SRI Biosciences as Director of Clinical Manufacturing

Jia-Hwa Fang, Ph.D., has joined SRI Biosciences as Director of Clinical Manufacturing. In this new role, he will lead a team to transfer and scale-up R&D, Good Laboratory Practice (GLP), and pilot formulations for early stage clinical trial materials.

Topics: Chemistry, Manufacturing + Controls (CMC) Clinical Laboratory Services Combinatorial Chemistry Drug Discovery Drug Formulation Development Drug Pipeline Pharmaceutical R+D Pharmaceutical Sciences: Analytical Chemistry Pharmaceutical Sciences: Stability Studies Pre-formulation Studies
Rathnam Chaguturu of SRI International
Rathnam Chaguturu Joins SRI's Center for Advanced Drug Research as Senior Director of Exploratory Research

Rathnam Chaguturu, Ph.D., has joined SRI International's Center for Advanced Drug Research as senior director of Exploratory Research.

Topics: Disease Focus Areas Drug Discovery Infectious Diseases Pharmaceutical R+D Pharmaceutical Sciences: Analytical Chemistry Proteomics
Researchers Developing New Multiple Sclerosis Drug That Can Be Taken Orally

Researchers at SRI are developing a new Multiple Sclerosis drug that can be taken by mouth. It will be more convenient than current treatments, which require frequent hospital visits for injections or intravenous infusions.

Topics: Alternative Drug Delivery Systems Drug Formulation Development Drug Pipeline Immunology + Inflammation Medicinal Chemistry Pharmaceutical R+D Pharmaceutical Sciences: Stability Studies Preclinical Drug Development
researchers in SRI lab
SRI International Awarded Contract Worth Up to $100M from National Institute of Allergy and Infectious Diseases

SRI International has been awarded a contract worth up to $100.5 million over 10 years from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH)

Topics: Disease Focus Areas Drug Discovery Immunology + Inflammation Infectious Diseases Metabolic Diseases Microbiology Pharmaceutical R+D Pre-formulation Studies Preclinical Drug Development Target Validation + Assay Development Vaccine Development
mosquito
SRI International and CTK Biotech Developing Low-Cost Diagnostic for Hard-to-Diagnose Chikungunya Virus

SRI International is working with CTK Biotech to develop a diagnostic assay for early detection of chikungunya that will provide results in less than 20 minutes—compared to the several hours it now usually takes.

Topics: Disease Focus Areas Infectious Diseases Pharmaceutical R+D Proteomics
chemotherapy research
SRI International and PhenoMatriX Collaborate to Develop Platin-Based Chemotherapies

SRI International, an independent nonprofit research and development organization, announced today that it is collaborating with PhenoMatriX (PMX), a biotechnology company, on the development of platin-based chemotherapies.

Topics: Basic Cancer Research Cancer Drug Discovery Drug Discovery Pharmaceutical R+D Preclinical Development Plans + Regulatory Services
SRI International Awarded National Institutes of Health Preclinical Services Contract

SRI International announced that it has been awarded a $20 million preclinical services contract by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

Topics: Basic Cancer Research Chemistry, Manufacturing + Controls (CMC) Developmental + Reproductive Toxicology Discovery ADMET and In Vitro Metabolism Disease Focus Areas Drug Formulation Development Genetic Toxicology Immunology + Inflammation Medical Imaging Medicinal Chemistry Pharmaceutical R+D Pre-formulation Studies Preclinical Development Plans + Regulatory Services Proteomics
SRI International Awarded Two National Cancer Institute Preclinical Development Service Contracts

SRI International has been awarded two National Cancer Institute (NCI) preclinical service contracts totaling $14.3 million. The contracts provide SRI up to $11.7 million for toxicology studies and an additional $2.6 million for pharmacology and pharmacokinetics studies.

Topics: Basic Cancer Research Cancer Drug Discovery Pharmaceutical R+D Preclinical Drug Development Safety Pharmacology
SRI International Begins NIAID-Funded Drug Evaluation Program for Tuberculosis

SRI International announced the initiation of a tuberculosis (TB) preclinical drug evaluation program in partnership with the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH).

Topics: Disease Focus Areas Infectious Diseases Pharmaceutical R+D

SRI In the News

Fighting Deadly Parasitic Infections with a UV Flashlight

This video interview with Ellen Beaulieu, a medicinal chemist at SRI International, shows how SRI researchers are using fluorescent dyes and a simple ultraviolet flashlight to create a test that can detect parasitic infections in human beings.

Topics: Biomarkers Drug Discovery Infectious Diseases Pharmaceutical R+D Proteomics
Jon Mirsalis
Fighting the War on Infectious Diseases: An Interview with SRI's Jon Mirsalis

Jon Mirsalis of SRI Biosciences describes how SRI researchers are developing drugs to fight infectious diseases like HIV, malaria, tuberculosis and the flu. Over the years, SRI has helped save thousands of lives by moving drugs from the early discovery stage into human clinical trials.

Topics: Discovery ADMET and In Vitro Metabolism Disease Focus Areas Infectious Diseases Pharmaceutical R+D

Events

pills
American Association of Pharmaceutical Scientists (AAPS) Annual Meeting

SRI Biosciences will exhibit.

Topics: Pharmaceutical R+D Preclinical Drug Development
scientist writing chemical symbols
American Society of Tropical Medicine and Hygiene (ASTMH) Annual Meeting

SRI Biosciences will exhibit.

Topics: Infectious Diseases Pharmaceutical R+D Proteomics

Divisions, Centers + Labs